Who owns ARROWHEAD PHARMACEUTICALS, INC. (ARWR)? Elite investor 13F holders
5 tracked elite investors reported holding ARROWHEAD PHARMACEUTICALS, INC as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC, Oaktree Capital Management, Gotham Asset Management, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 35176456.00 USD | 431560.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 38221751.00 USD | 468921.000000 | Shares | reduce | Original filing |
| Oaktree Capital Management | ARROWHEAD PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 10951820.00 USD | 9146000.000000 | Principal | buy | Original filing |
| Bridgewater Associates | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Gotham Asset Management | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 545791.00 USD | 6696.000000 | Shares | reduce | Original filing |
| Polen Capital Management | ARROWHEAD PHARMACEUTICALS IN | SHARE | 2026-06-30 | 2026-08-04 00:00:00 | 538944.00 USD | 6612.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.